Canada: Canada-EU Free Trade Deal: Intellectual Property Issues For The Pharmaceutical Industry

Last Updated: October 27 2013
Article by Xavier Van Overmeire and Sam Pathmasiri


Canada and the European Union (the "EU") have signed a tentative deal to open markets and drop nearly all import taxes on everything from food to cars. Under the Comprehensive Economic Trade Agreement (the "CETA") and NAFTA, Canada will have preferential access to more than half of the world's economy. The agreement also provides for working groups to look at non-tariff barriers — regulations on health and sanitation, for example — that interfere with trade.

Such an economic agreement with the EU will provide Canadian pharmaceutical companies with preferential access to a market of 503 million consumers. CETA shall exceed the scope of the North American Free Trade Agreement (which is part of "first generation" series agreements), and inscribes itself as part of a new series of "second generation" agreements. CETA, as the agreements of first generation, continues to cover trade in goods and services. However, in the second generation agreements, added emphasis is placed on dismantling non-tariff barriers such as public procurements, the protection of IP rights, competition, mutual recognition of professional qualifications, sustainable development, environment, education and investment. This agreement will allow EU companies to compete with US exporters on the Canadian market by leveling the playing field, in addition to benefitting from preferential treatment going beyond NAFTA.

Main differences between Canada and the EU regarding IP

With respect to the protection of IP rights, CETA establishes standards which supersede those of the Agreement on Trade-Related Aspects of Intellectual Property Rights ("TRIPS"). For instance, the protection of IP rights has been particularly strengthened by extending the length of protection. In this respect, the EU and Canada have different levels of protection, as summarized in the following table:

In Canada, the patent's term was increased from 17 to 20 years in 1989 to comply with Canada's international commitments (including TRIPS1, which provides for a minimum of twenty years of protection). However, in practice and especially in the pharmaceutical industry, the length of commercial exploitation of patents is actually reduced due to clinical trials and obtaining the notice of compliance ("NOC"). In fact, the commercial life of a patent for an innovative drug is about ten years on average: which is half the term of patent protection in Canada. The approval period for a patent application can take four years and on average, it takes six years to complete the clinical trials and obtain a NOC. Note also that such delays are higher than in other industrialized countries.

In Europe, the patent regime takes into account the "commercial" shortening of the patent lifespan resulting from the delays in obtaining an authorization to commercialize (the "AC") before the products are put on the market. In order to promote research and development of innovative drugs, the EU compensates for the loss of time caused by the administrative authorization process through the "Certificate of Complementary Protection", which can extend the lifetime of a patent for a maximum of five years where the application meets certain criteria. The Canadian regime does not provide for such an extension on patent protection. 

In addition, the EU regime provides for a ten year protection period on the clinical data collected by innovative pharmaceutical industries on the condition that they comply with their obligations under the AC. This protection covers data collected by a company during its clinical trials.  However, after a period of eight years, the clinical data pertaining to the original drug can be used to prepare an AC request by the generic industry, which can then be approved at the expiration of the ten year protection period. Furthermore, an additional protection of one year is available to the original drug manufacturer if it can demonstrate that during the initial eight years of commercial exclusivity it had obtained an AC for one or several new therapeutic indications.

Furthermore, to encourage the pharmaceutical industry to develop their research with respect to drugs intended to treat rare diseases and "orphan" drugs, the EU chose to grant innovative companies a full exclusivity period of ten years.

Thus, the level of protection is higher in Europe and much emphasis is placed on protecting R&D results.

The differences benefit the Canadian generic industry. Indeed, the lower level of protection in Canada actually benefits the generic industry and its competitiveness on the European market, since it allows companies to commercialize their generics before their European competitors. However, while this latter segment of the pharmaceutical industry stands to benefit, the innovative companies remain adversely affected by the Canadian regime as the comparatively lesser duration of protection limits their commercial exclusivity in Canada. Since Europe has longer protection of intellectual property rights, the generic drugs produced by a European company are available on the European market at a later time in comparison to Canada.

Negotiations requirements of the EU

During negotiations, the EU had made three requests: (1) An extension of the legal duration of patents; (2) The duration of the exclusive data protection must expand the scope of its application and shall be extended to at least ten years from the issuance of the Notice of Compliance Regulations (the "NOC") and to at least eleven years if, during the eight first years following the issuance of the NOC, the innovative pharmaceutical company obtains an authorization to process one or several new therapeutic indications; (3)The reinforcement of patent holder rights under the NOC regulations by offering a right of appeal of any Court decision granting NOC to commercialization of a generic drug.

It will be interesting to see if the provision of the final text, when it is published, will include such requirements. Meeting these EU requirements would therefore in turn require many modifications to the Canadian legislation, namely the Food and drug Regulation, the Notice of Compliance Regulations and the Patent Act. It can possibly lead to the creation of new regulations supporting those modifications.


The CETA can significantly modify the Canadian IP landscape for the pharmaceutical industry. This has brought about  significant controversy regarding the balance between the protection granted to patent holders on one side and the accessibility (in terms of price) for the consumer on the other side.

From the innovative pharmaceutical industry's perspective, changes leading to an extension of the exclusive commercialization period would allow it to better absorb the cost of research. This would in turn represent an incentive for innovators to push their research even further. This might promote greater investment in R&D in Canada. However, this hypothesis is tempered by the fact that according to some observers, there is no direct correlation between an extension of IP protection and increased investment in R&D. 

Nevertheless, this extension of the IP protection duration would be a significant challenge for the generic industry in Canada. Similarly, the delay in the commercialization of the generic products will lead to a rise in cost for medication and will increase costs for provincial authorities, which bear this burden since they will have to wait longer before having access to generic drugs.

About Dentons

Dentons is a global firm driven to provide you with the competitive edge in an increasingly complex and interconnected marketplace. We were formed by the March 2013 combination of international law firm Salans LLP, Canadian law firm Fraser Milner Casgrain LLP (FMC) and international law firm SNR Denton.

Dentons is built on the solid foundations of three highly regarded law firms. Each built its outstanding reputation and valued clientele by responding to the local, regional and national needs of a broad spectrum of clients of all sizes – individuals; entrepreneurs; small businesses and start-ups; local, regional and national governments and government agencies; and mid-sized and larger private and public corporations, including international and global entities.

Now clients benefit from more than 2,500 lawyers and professionals in 79 locations in 52 countries across Africa, Asia Pacific, Canada, Central Asia, Europe, the Middle East, Russia and the CIS, the UK and the US who are committed to challenging the status quo to offer creative, actionable business and legal solutions.

Learn more at


1. The WTO Agreement on TRIPS, negotiated during the Uruguay Round, which took place from 1986 to 1994, introduced, for the first time, rules relating to IP in the multilateral trading system. Section 33 requires a minim of 20 years protection for patents.

For more information, visit our Doing Business in Canada blog at

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. Specific Questions relating to this article should be addressed directly to the author.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions